Cheng, Jordan
Zink, Joke
O’Neill, Edward
Cornelissen, Bart
Nonnekens, Julie
Livieratos, Lefteris
Terry, Samantha Y. A. http://orcid.org/0000-0002-6497-6681
Funding for this research was provided by:
Medical Research Council (MR/N013700/1)
Rosetrees Trust (PhD2022\100001)
Wellcome Trust (WT203148/Z/16/Z, WT212885/Z/18/Z)
Cancer Research UK (C7893/A28990)
Engineering and Physical Sciences Research Council (EP/S032789/1)
European Research Council (101042537;RADIOBIO)
Article History
Received: 22 May 2024
Accepted: 29 July 2024
First Online: 13 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: JN is consultant at Novartis. BC has acted as a consultant for Theranostics. JN receives research funding from Quirem Medical, a Terumo company and from POINT Biopharma, a Lilly company. BC previously received financial support from BET for non-related work. ST receives support from Perspective Therapeutics (not related to this project). BC holds several patents on radiopharmaceuticals, all non-related to this work.